| Autor: |
Xin Zhang, Jiandong Wang, Yali Fan, Ziyi Zhao, Sarah E. Paraghamian, Gabrielle M. Hawkins, Lindsey Buckingham, Jillian O’Donnell, Tianran Hao, Hongyan Suo, Yajie Yin, Wenchuan Sun, Weimin Kong, Delin Sun, Luyu Zhao, Chunxiao Zhou, Victoria L. Bae-Jump |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of cancer research and clinical oncology. |
| ISSN: |
1432-1335 |
| Popis: |
Purpose Although paclitaxel is a promising first-line chemotherapeutic drug for ovarian cancer, acquired resistance to paclitaxel is one of the leading causes of treatment failure, limiting its clinical application. Asparagus officinalis has been shown to have anti-tumorigenic effects on cell growth, apoptosis, cellular stress and invasion of various types of cancer cells and has also been shown to synergize with paclitaxel to inhibit cell proliferation in ovarian cancer. Methods Human ovarian cancer cell lines MES and its PTX-resistant counterpart MES-TP cell lines were used and were treated with Asparagus officinalis and paclitaxel alone as well as in combination. Cell proliferation, cellular stress, invasion and DMA damage were investigated and the synergistic effect of a combined therapy analyzed. Results In this study, we found that Asparagus officinalis combined with low-dose paclitaxel synergistically inhibited cell proliferation, induced cellular stress and apoptosis and reduced cell invasion in paclitaxel-sensitive and -resistant ovarian cancer cell lines. The combined treatment effects were dependent on DNA damage pathways and suppressing microtubule dynamics, and the AKT/mTOR pathway and microtubule-associated proteins regulated the inhibitory effect through different mechanisms in paclitaxel-sensitive and -resistant cells. Conclusion These findings suggest that the combination of Asparagus officinalis and paclitaxel have potential clinical implications for development as a novel ovarian cancer treatment strategy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink